INTRODUCTION
The muscle sarcomere is a complex and highly ordered array of numerous proteins and the precise organization and alignment of these proteins are essential for proper muscle function. Interaction between thick and thin filaments causes sliding between these two filaments, resulting in muscle contraction. Thick filaments consist predominantly of myosin with several myosin-associated proteins. These myosinassociated proteins are important for integration and maintenance of sarcomeres.
Cardiac myosin-binding protein-C (MyBP-C), also known as C-protein, is one of the major myosin-binding proteins in vertebrate striated muscles with an approximate molecular mass of 140 kDa (Offer et al., 1973; Pepe and Drucker, 1975) . MyBP-C is localized to the central cross-bridge zone in each half of the A-band region of myofibrils (Pepe and Drucker, 1975; Craig and Offer, 1976) . MyBP-C modulates myosin assembly (Offer et al., 1973) , actin-myosin interaction in sarcomeres (Moos et al., 1978; Hartzell, 1985) , and stabilizes thick filaments (Moos et al., 1978) . In addition, MyBP-C interacts with connectin/titin, which is important for the precise arrangement of actin-myosin filaments in sarcomeres (Maruyama, 1986; Fü rst et al., 1992; Koretz et al., 1993) .
MyBP-C, a member of the intracellular immunoglobulin (Ig) superfamily, has three isoforms, two skeletal (fast-and slow-) and one cardiac type encoded by three distinct genes. The two skeletal types of MyBP-C are composed of a total of 10 domains: seven IgI domains and three fibronectin (FN) type III repeats (Einheber and Fischman, 1990; Fü rst et al., 1992; Okagaki et al., 1993; Weber et al., 1993; Harpaz and Chothia, 1994; Kurasawa et al., 1999) , whereas, cardiac MyBP-C has 11 domains (C0 -C10): eight IgI domains (instead of seven in the skeletal types) and three FN type III repeats ( Figure 1A ). In addition, cardiac MyBP-C has a unique phosphorylation domain between the C1 and C2 domain (Kasahara et al., 1994; Gautel et al., 1995; Yasuda et al., 1995; Yang et al., 1998) . Through these domains, MyBP-C interacts with other sarcomeric proteins; C1-C2 domains interact with the S2 segment of myosin, C10 domain with light meromyosin (LMM), and C8 -C10 with connectin/titin.
All isoforms of MyBP-C are specific for different muscle fiber types and different developmental stages (Obinata et al., 1984; Obinata, 1985; Bähler et al., 1985; Kawashima et al., 1986; Fougerousse et al., 1998; Gautel et al., 1998; Kurasawa et al., 1999) . In humans and mice, expression of the cardiactype isoform is restricted to the heart through development, and no splicing variants of the cardiac isoform have been reported (Fougerousse et al., 1998; Gautel et al., 1998; Kurasawa et al., 1999) . On the other hand, the chicken cardiac isoform containing the specific phosphorylation domain is abundantly expressed in cardiac muscle through development; however, an alternative spliced variant lacking the phosphorylation domain is expressed dominantly but transiently in embryonic skeletal muscle (Bähler et al., 1985; Yasuda et al., 1995; Mohamed et al., 1998) .
Mutations in the gene MYBPC3, encoding human cardiactype MyBP-C, have been identified to cause modest and late-onset familial hypertrophic cardiomyopathy (Bonne et al., 1995; Watkins et al., 1995; Carrier et al., 1997; Rottbauer et al., 1997; Yu et al., 1998) . Familial hypertrophic cardiomyopathy is an autosomal dominant disease with typical morphological changes, including cardiomyocyte hypertrophy and/or myofibrillar disarray with fibrosis (Maron et al., 1987a,b; Seidman and Seidman, 2001 ). Most of the mutations found in the MYBPC3 are predicted to lead to the altered mRNA sequence and to produce the carboxyl-terminal truncation of the cardiac MyBP-C polypeptides lacking the C10 myosin binding site, or in some cases, lacking the C8 -C10 connectin/titin binding site (Bonne et al., 1995; Watkins et al., 1995; Carrier et al., 1997; Kimura et al., 1997; Rottbauer et al., 1997; Yu et al., 1998) . These findings demonstrate that the expression of mutant sarcomeric proteins, such as the truncated cardiac MyBP-C, induce cardiac dysfunction and alteration of myofibrils in cardiomyocytes. However, the precise mechanism for this negative effect has not yet been determined.
Herein, we identified a novel isoform of mouse cardiac MyBP-C mRNA, namely, MyBP-C(ϩ), that has an additional 30 nucleotides by alternative splicing and encodes exactly the same amino acid sequence as previously reported, but contains an additional 10 amino acids in the connectin/titin binding region. MyBP-C(ϩ) decreased binding to myosin filaments and connectin/titin in vitro. Green fluorescent protein (GFP)-tagged MyBP-C(ϩ) did not correctly localize to sarcomeres, and it disrupted the A-band formation in chicken cardiomyocytes. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that mRNA encoding MyBP-C(ϩ) was dominantly expressed in the aged mouse atrium. The cardiac-specific phosphorylation domain is shown as a shaded square (P). Position of 10 amino acids insertion is indicated in C9 domain. (B) Genomic sequence and deduced amino acid sequence encoding the C9 IgI domain of mouse cardiac MyBP-C. The nucleotide sequence of the coding region and the deduced amino acid sequence of MyBP-C(ϩ) are represented in capital letters. Exon 30 and 31B are highlighted by hatch. MyBP-C(ϩ)-specific insert sequence (exon 31A) is indicated by a box. Arrows indicate the location of primer F (#F), primer I (#I) and primer R (#R). Asterisks indicate a 5Ј splice donor sequence, gt, and 3Ј splice acceptor sequence, CAG. (C) Identification of MyBP-C(ϩ) in C57BL/6J and ICR mice. cDNA libraries prepared from 8-wk-old C57BL/6J hearts (lane 1 and 2) or from ICR hearts (lane 3 and 4) were subjected to PCR by using a primer F ϩ R set (lane 1 and 3) or using a primer F ϩ I set (lane 2 and 4). Primer F ϩ R set amplifies 212-base pair and 182-base pair DNA fragments which are generated from MyBP-C(ϩ) and MyBP-C(Ϫ) cDNA, respectively. Primer F ϩ I set specifically detects MyBP-C(ϩ) cDNA as a 118-base pairs product. A molecular weight marker (MW) indicates 400, 300, 200, and 100 base pairs, top to bottom. (D) Schematic genomic structure of mouse cardiac MyBP-C. Both MyBP-C(Ϫ) and MyBP-C(ϩ) mRNAs are encoded by a single gene and generated by an alternative mRNA splicing.
MATERIALS AND METHODS

cDNA and Sequencing
A cDNA clone encoding "insert-plus" mouse cardiac MyBP-C [MyBP-C(ϩ)] was isolated from a 12-wk-old mouse BALB/c heart cDNA library (BD Biosciences Clontech, Palo Alto, CA) among several "insert-minus" mouse cardiac MyBP-C [MyBP-C(Ϫ)] cDNAs reported previously (Kasahara et al., 1994) . The newly isolated clone and previously isolated clone were sequenced with a SequiTherm EXCEL2 Long-Read DNA sequencing kit-LC (Epicentr, Madison, WI) or a Thermo Sequenase Cy5.5 dye terminator cycle sequencing kit (Amersham Biosciences UK, Little Chalfont, Buckinghamshire, United Kingdom). Analysis of DNA sequence data was carried out with the GENETYX program (SDC Software, Tokyo, Japan). Consequently, we found some errors on the nucleotide and amino acid sequences encoding MyBP-C(Ϫ) reported previously and then corrected them here; T 441 was revised to C (no change in the encoded amino acid sequence), a G was inserted at 2638, and a C was deleted at 2700; therefore, the amino acid sequence QSMP-WECPGPALPLSPSCLL (844 -863) was replaced with AVNAVGM-SRPSPASQPFMPI.
PCR and RT-PCR Samples and Primers
In this study, we used two cDNA libraries: one was prepared from total RNA isolated from 8-wk-old ICR mouse hearts by using reverse-transcription with oligo-dT primers (Chomczynski and Sacchi, 1987 ) and the other was prepared from 8-wk-old C57BL/6J (SuperScript mouse heart cDNA library; Invitrogen, Carlsbad, CA).
Messenger RNAs were extracted using a QuickPrep MicromRNA purification kit (Amersham Biosciences UK) from ventricles and atria of newborn, 4-wk-, 8-wk-, and Ͼ6-mo-old ICR mice. These mRNAs were reverse-transcripted with oligo-dT primers. The following primers were used for PCR reactions: primer F, 5Ј-TCAAT-GTGGCTCTGGAGTGG-3Ј (3335-3354); primer R, 5Ј-GAAGAC-CCGGAAGTAGTAGC-3Ј (3527-3546); and primer I, 5Ј-AGGAT-GGTGAAGGAAGGGAG-3Ј (3433-3452).
Genomic tail DNA was prepared from ICR mice according to the method described by Blin and Stafford (1976) . By a PCR reaction with a primer F ϩ R set, the genomic DNA fragment was isolated, sequenced, and a comparison with human cardiac MyBP-C genomic DNA sequence (accession no. U91629, Entrez) was made to define the exon-intron structure.
Generation of Recombinant MyBP-Cs by Using a Baculovirus Expression System and the Binding Assay
Both of the XhoI-EcoRI fragments encoding full-length MyBP-C(Ϫ) and MyBP-C(ϩ) were subcloned into pBlueBacHis2A (Invitrogen). Preparation of recombinant viral DNA was performed using a Bac-N-Blue transfection kit (Invitrogen) according to the technical bulletin. Consequent recombinant MyBP-Cs with histidine tags were purified from lysates of sf9 cells by using a HiTrap affinity column (Amersham Biosciences UK), which was saturated with nickel ions, and then dialyzed against binding buffer (0.1 M KCl, 20 mM imidazole-HCl, pH 7.0). The supernatant separated by centrifugation at 50,000 rpm for 30 min (TLA-100; Beckman Coulter, Fullerton, CA) was used for the binding reactions.
Crude myosin was prepared from rabbit ventricles as described previously (Perry, 1955) , and the myosin was purified using DEAESephadex A-50 (Richards et al., 1967) . Reconstitution of myosin filaments was performed during a dialysis against the binding buffer. ␤-Connectin prepared from chicken pectoralis muscle (Kimura and Maruyama, 1983) , which was kindly provided by Dr. S. Kimura (Chiba University, Chiba, Japan), was dialyzed against the binding buffer. Quantitations of the MyBP-Cs, reconstituted myosin filaments, and ␤-connectin were performed by a bicinchoninic acid protein assay reagent kit (Pierce Chemical, Rockfold, IL).
For binding assays, recombinant MyBP-C(Ϫ) or MyBP-C(ϩ) at varying concentrations was incubated with reconstituted myosin filaments (0.5 M) or ␤-connectin (0.04 M) for 30 min at 4°C, and then centrifuged at 50,000 rpm for 30 min. Supernatants and pellets were subjected to SDS-PAGE, stained with Coomassie Blue, scanned with a densitograph (Atto, Tokyo, Japan), and analyzed using NIH Image.
Vector Constructs
Using a Transformer site-directed mutagenesis kit (BD Biosciences Clontech), each A 106 in the cDNA encoding mouse cardiac MyBP-C(Ϫ) and MyBP-C(ϩ) was substituted to G. The XhoI-EcoRI fragment encoding the full length of MyBP-C(Ϫ) open reading frame and that of MyBP-C(ϩ) open reading frame were subcloned into pEGFP-C3 (BD Biosciences Clontech), and the vector was named pGMC(Ϫ) or pGMC(ϩ), respectively. To construct pGMC⌬7-10, the pGMC(Ϫ) was partially digested with ApaI and then ligated. As for the pGMC⌬9-10, the pGMC(Ϫ) was digested at the EcoRV site and the BamHI site and then blunted and ligated by a Blunting Kit (Takara Bio., Kyoto, Japan). To construct pGMC⌬10(Ϫ) and pGMC⌬10(ϩ), the pGMC(Ϫ), and the pGMC(ϩ) were digested, respectively, with HindIII and BamHI, and then blunted and ligated by the blunting kit.
Cell Culture and Transfection
Cardiac myocytes were prepared from chicken embryos at embryonic day 9 -10, according to Lin et al. (1989) . Chick ventricles were incubated in 4 ml of trypsin solution (0.125% trypsin in phosphatebuffered saline (PBS) containing 1 mM EGTA) for 5 min at room temperature. The supernatant containing dispersed cells was placed into 25 ml of growth medium (10% fetal calf serum, 10 U/ml penicillin, 10 g/ml streptomycin in minimal essential medium with l-glutamine and Earle's salts; Invitrogen). The remaining tissue fragments were incubated in 4 ml of the fresh trypsin solution as described above, and the dispersed cells were harvested for an additional two times. The cell suspension was filtered to remove large clumps of cells and then centrifuged for 5 min. Cells were plated for 1 h at 37°C in a humidified 5% CO 2 incubator (Hyde et al., 1969) . The supernatant containing floating myocytes was collected and centrifuged for 5 min. The cells were resuspended in growth medium, grown on glass coverslips at an initial density of 1-2 ϫ 10 5 cells/35-mm dish. The following day, cells were transfected with the expression vector using Effectene transfection reagent (QIA-GEN, Tokyo, Japan).
Indirect Immunofluorescence Microscopy and Immunoblotting
Three days after transfection, cells were rinsed with PBS and fixed with 10% formalin in PBS for 15 min. The cells were then permeabilized with 0.2% Triton X-100 in PBS for 10 min. Atrial and ventricular tissues isolated from ICR mice Ͼ20 mo of age were prefixed with 4% paraformaldehyde in PBS for 30 min, followed by immersion in liquid nitrogen-cooled isopentane. The longitudinal frozen sections (3 m) were fixed with 4% paraformaldehyde in PBS for 10 min. After rinsing repeatedly with PBS, the cells and the sections were blocked with 1% bovine serum albumin in PBS and incubated with primary antibodies for 1 h. After repeated washing with 1% bovine serum albumin in PBS, they were incubated with rhodamine-conjugated goat anti-rabbit IgG or anti-mouse IgG as secondary antibodies for 1 h. After a final washing with PBS, the specimens were mounted in 50% glycerol in PBS. All steps were carried out at room temperature. Samples were examined with an Axioskop (Carl Zeiss, Jena, Germany) with a cooled charge-coupled device camera, CoolSNAP (Nippon ROPER, Chiba, Japan,) or with an Axiovert 135 TV (Carl Zeiss) with a cooled charge-coupled device camera, PXL37 (Photometrics, Tucson, AZ).
For immunoblotting, proteins were transferred to nitrocellulose membranes (Towbin et al., 1979) . Membranes were treated with 5% skimmed milk in tris-buffered saline for 1 h and then incubated with primary antibody followed by treatment with alkaline phosphataseconjugated secondary antibody. The membrane was washed with Tris-buffered saline and stained with nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt in alkaline phosphatase buffer (0.1 M NaCl, 2 mM MgCl 2 , 0.1 M Tris-HCl, pH 9.5).
Primary Antibodies
The following primary antibodies were used: C315, a monoclonal antibody specific for chicken cardiac MyBP-C (Kawashima et al., 1986) ; ␣ccp, a polyclonal antibody that recognizes both chicken and mouse cardiac MyBP-C and reacts with both MyBP-C(Ϫ) and MyBP-C(ϩ) (Yasuda et al., 1995) ; A4.1045, a monoclonal antibody against the sarcomeric myosin heavy chain developed by Helen M. Blau (obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA); and Pc72C, a polyclonal antibody against the carboxyl-terminal (M-line) region of connectin/titin was kindly provided from Dr. S. Kimura (Chiba University) (Soeno et al., 1999) .
Statistical Analysis
To study the influence of the expression of MyBP-C variants on the endogenous cross-striated sarcomeres in cardiomyocytes, cells were transfected with plasmids and 3 d later, processed for immunostaining as described above. The percentage of cells expressing the MyBP-Cs and exhibiting alteration of sarcomeres as observed after staining with A4.1045 was determined for each cover glass. The data obtained from three independent transfections were analyzed. For each construct, three coverglasses were examined and between 240 and 394 transfected cells were scored. The data were analyzed by one-way analysis of variance followed by the multiple comparison analysis with the test of Ryan (Ryan, 1959 (Ryan, , 1960 .
RESULTS
Isolation of a Variant of Cardiac MyBP-C
One of the major myosin binding proteins, cardiac MyBP-C/C-protein localizing at A-bands consists of eight IgI domains ( Figure 1A , open square) and three FN type III repeats ( Figure 1A , circle). We isolated a novel variant of cardiac MyBP-C cDNA from a 12-wk-old BALB/c mouse heart cDNA library, which we previously used for isolating a full-length cDNA (Kasahara et al., 1994) . The novel cDNA of ϳ4.2 kb, encodes identical eight IgI and three FN type III repeats, except for an additional 30 bases insertion located at the 5Ј end of the exon 31, which was previously reported as an intron sequence between exon 30 and exon 31 ( Figure 1B , exon 31A, sequence in the box). The insertion does not result in a frame-shift mutation, nor does it contain a termination codon. Therefore, this cDNA encodes the entire amino acids of the mouse cardiac-type MyBP-C with an extra10 amino acids in the C9 domain ( Figure 1A , insertion), which is important for connectin/titin binding (Freiburg and Gautel, 1996) and incorporation into sarcomeres (Gilbert et al., 1996) . We term the previously reported cardiac MyBP-C as insertminus or MyBP-C(Ϫ) and the novel variant MyBP-C containing the extra amino acids as insert-plus or MyBP-C(ϩ).
To confirm that the MyBP-C(ϩ) cDNA was not an artifact of the cDNA library used, two additional cDNA libraries prepared from whole hearts of 8-wk-old C57BL/6J mice or ICR mice were screened by PCR. As shown in Figure 1B , a combination of primer F and R was designed to recognize both the insert-plus (212-base pair products) and the insertminus cDNA (182-base pair products) and a combination of primer F and I was designed only for amplifying the insertplus cDNA (118 base pairs). As shown in Figure 1C (lane 1) , the PCR reaction with an F ϩ R primer set amplified a 182-base pair PCR product representing MyBP-C(Ϫ) with an additional few bands with higher molecular weight, including a 212-base pair product in the C57BL/6J cDNA library. The nucleotide sequence confirmed that the 212-base pair PCR product contains exon 31A. When we used an F ϩ I primer set, a 118-base pair PCR product from MyBP-C(ϩ) was clearly amplified in the same cDNA library ( Figure 1C , lane 2). Although the 212-base pair MyBP(ϩ) products were hardly detected in the ICR cDNA library ( Figure 1C, lane 3) , the 118-base pair products were clearly detected ( Figure 1C , lane 4). These results demonstrate the expression of cardiactype MyBP-C(ϩ) in all the cDNA libraries examined and its expression is significantly lower than that of MyBP-C(Ϫ).
Genomic Southern blotting demonstrated that a single gene encodes mouse cardiac MyBP-C (Harris et al., 2002) . Therefore, MyBP-C(ϩ) and MyBP-C(Ϫ) are expected be generated from a single gene, with an identical sequence except for the 30-base pair nucleotides insertion in MyBP-C(ϩ), which is coded in the genomic region previously reported as an intron. In addition, two consensus splice acceptor sequences CAG ( Figure 1B , *) were located next to the newly identified exon 31A and the known exon 31B with a consensus 5Ј splice donor sequence gt ( Figure 1B , *) located at the 5Ј end of intron next to the coding sequence (exon 30), which is identical to the sequence of MyBP-C(Ϫ) as we described previously (Kasahara et al., 1994) . Therefore, we concluded that both MyBP-C(ϩ) and MyBP-C(Ϫ) mRNAs were encoded by a single gene and generated by an alternative splicing ( Figure 1D ).
MyBP-C(؉) Reduced the Binding Affinity to Myosin Filaments and Connectin/Titin
The 10 amino acid insert encoded by exon 31A is located at the C9 domain, a domain that interacts with connectin/titin ( Figure 1A) . Therefore, we examined whether this insert affects its binding to connectin/titin. Full-length MyBP-C(Ϫ) or MyBP-C(ϩ) protein were produced in sf9 cells by using a baculovirus expression system and were used for a cosedimentation assay with reconstituted myosin filaments as well as ␤-connectin.
MyBP-C(Ϫ) or MyBP-C(ϩ) was mixed with reconstituted myosin filaments prepared from rabbit cardiac muscles for 30 min at 4°C. Representative results obtained using 0.5 M cardiac myosin and 0.15 M recombinant MyBP-C(Ϫ) or 0.17 M MyBP-C(ϩ) are shown in Figure 2A . Before mixing, the majority of myosin fractionated to pellets (P) (lane 2), whereas MyBP-C fractionated to supernatants (S) (lanes 3 and 7). When MyBP-C was mixed with reconstituted myosin, MyBP-C bound to myosin fractionated in pellets (lanes 6 and 10) and unbound MyBP-C stayed in supernatants (lanes 5 and 9). Densitometric analysis showed that 40% of MyBP-C(Ϫ) or 20% of MyBP-C(ϩ) was associated with the myosin filaments under this experimental condition.
To analyze the binding of MyBP-C proteins more precisely, various concentrations of MyBP-C proteins were mixed with a constant concentration of myosin (0.5 M). Baculovirus derived MyBP-C(Ϫ) was found to bind to myosin with a molar ratio of ϳ0.5:1 at the saturated concentration which is similar to that of native MyBP-C (0.6:1) as reported previously (Alyonycheva et al., 1997) (Figure 2B , left). At a concentration between 0 and 0.4 M, which is below the saturating concentration, MyBP-C(Ϫ) binds myosin with higher affinity than that of MyBP-C(ϩ) (Figure 2B , right).
Similar results were obtained using ␤-connectin purified from chicken pectoralis muscle. Using 0.04 M ␤-connectin mixed with 0.1 M MyBP-C(Ϫ) or 0.13 M MyBP-C(ϩ) demonstrated that MyBP-C(ϩ) ( Figure 2C , lane 10) had a weaker interaction with ␤-connectin than that of MyBP-C(Ϫ) ( Figure 2C, lane 6 ). These results demonstrate that an insertion of 10 amino acids into the connectin/titin binding domain of MyBP-C resulted in decreased affinity to connectin/ titin as well as myosin.
MyBP-C(؉) Does Not Effectively Assemble into Sarcomeres
Multiple reports described that carboxyl-terminus deletion mutants of cardiac as well as skeletal MyBP-C, either deleting the myosin binding domain (C10) or the connectin/titin binding domain (C8 -C10), resulted in diffusely localized MyBP-C protein impairing the endogenous sarcomeric structure in transfected cells (Gilbert et al., 1996; McConnell et al., 1999 McConnell et al., , 2001 Yang et al., 1998 Yang et al., , 1999 Flavigny et al., 1999) . Therefore, we asked whether this 10 amino acid insertion in C9 domain modifies its assembly into sarcomeres. GFPtagged expression vectors encoding MyBP-C(ϩ) or MyBP-C(Ϫ), as well as a series of carboxyl-terminus deletion mutants were generated ( Figure 3A ): GMC(ϩ) represents GFPtagged full-length MyBP-C(ϩ), GMC(Ϫ), GFP-tagged fulllength MyBP-C(Ϫ), GMC⌬7-10, GMC(Ϫ) with deletion of C7 to C10, GMC⌬9-10, a deletion mutant without C9 and C10, GMC⌬10(ϩ), GMC(ϩ) with a deletion of C10 and GMC⌬10(Ϫ), GMC(Ϫ) with a deletion of C10.
These vectors were transfected into chicken cardiomyocytes and protein expression was confirmed by Western blotting by using anti-MyBP-C antibody (␣ccp). GFP-tagged full-length MyBP-C(Ϫ) [GMC(Ϫ)] or MyBP-C(ϩ) [GMC(ϩ)] proteins migrated at a slightly higher molecular weight (arrowheads) than that of endogenous chicken cardiac MyBP-C (arrow). A series of carboxyl-terminus deletion mutants were also detected with anti-MyBP-C antibody (␣ccp) (Figure 3B , arrowheads) and anti-GFP antibody (our unpublished data).
After confirming the molecular size of the GFP-fused various MyBP-C protein constructs, we examined the intracel- lular localization of these proteins. First, we examined the localization of nonfused GFP proteins. The majority of GFP proteins were diffusely localized in the cytoplasm ( Figure  4A ). Some nonfused GFP proteins were broadly incorporated into the sarcomere structure and showed overlapping staining with myosin ( Figure 4B , red) that was observed in 51% of the total of 240 transfected cells (Figure 4 , A and B and Table 1 ). However, GFP signals were not completely colocalized with myosin (red color), and the strong green GFP signals were easily detected at the gap between the A-bands (M lines) (enlarged image in Figure 4B ). When GFP proteins were detected in myofibrils, 93% of cells showed organized sarcomere structure (Figure 4 , A and B, and Table  1 ). This indicates that GFP proteins nonspecifically associate with myofibrils, but these proteins do not have deleterious effects on sarcomere organization.
In Interestingly, in the 73% of cells expressing GFP-MyBP-C(ϩ) proteins, they diffusely localized in the cytoplasm without forming striated sarcomere structures ( Figure 5 , A and C, and Table 1 ). However, GFP-MyBP-C(ϩ) proteins were detected as filamentous structure and were not concentrated at the M-line (Figure 4 , A and B versus Figure 5 , E and J). In rest of the cells (27%), GFP-MyBP-C(ϩ) proteins colocalized with myofibrils ( Figure 5, E and H) .
When GFP-MyBP-C(ϩ) proteins were diffusely localized, 57% of the cells showed well-organized sarcomeric myosin staining ( Figure 5B ) and 43% of cells did not ( Figure 5D ). When GFP-MyBP-C(ϩ) were detected in the myofibrils, only 21% of cells showed organized sarcomere structure and 79% of these cells displayed somewhat disorganized sarcomere structure detected with anti-myosin antibody (Figure 5 , E-G) and anti-connectin/titin antibody ( Figure 5 , H-J). In addition, we sometimes detected condensed GFP signals in the cytoplasm (our unpublished data). These data are summarized in Table 1 .
These results indicate that GFP-MyBP-C(Ϫ) was effectively incorporated into sarcomere structures and colocalized with the endogenous MyBP-C protein; however, GFPMyBP-C(ϩ) was not effectively targeted to A-bands. When GFP-MyBP-C(ϩ) proteins were incorporated myofibrils along with myosin filaments or connectin/titin ( Figure 5 , E-J, arrow), sarcomere structures were significantly disturbed (p ϭ 0.0004, multiple analyses using the test of Ryan; Table 1 ). This suggests that MyBP-C(ϩ) has dominant negative effects on sarcomere organization.
Alteration of Sarcomere Structure by MyBP-C(؉) or Carboxyl-Terminus Deletion Mutants
To further examine the effects of MyBP-C(ϩ) on sarcomere structure, we compared it to several carboxyl-terminus deletion mutants that have been shown to disorganize sarcomere structure ( Figure 3A ) (Gilbert et al., 1996; Flavigny et al., 1999) . Consistent with previous reports, 60 -74% of transfected cells showed diffusely localized carboxyl-terminus deletion mutants (Table 1) . Altered sarcomere structure was also detected in 53% of the cells expressing GMC⌬7-10 mutants, 57% of GMC⌬9-10, 65% of GMC⌬10(ϩ), and 77% of GMC⌬10(Ϫ) (Figure 6 , *p Ͻ 0.001). Accordingly GMC⌬10(Ϫ) showed the most severe effects on sarcomere disorganization, which was significantly higher than GMC⌬9Ϫ10, GMC⌬7Ϫ10, and GFP-MyBP-C(ϩ) (Figure 6 , †p Ͻ 0.01).
In atria, the level of the expression of MyBP-C(Ϫ) mRNA detected as a 182-base pair product was dominant at the newborn stage and 4 wk of age, and then it gradually decreased at 8 wk and Ͼ6 mo of age. In contrast, the expression of the 212-base pair products representing MyBP-C(ϩ) gradually increased and was dominant Ͼ6 mo of age. In ventricles, 182-base pair product of MyBP-C(Ϫ) mRNA was dominantly expressed at all stages examined and 212-base pair product of MyBP-C(ϩ) was detected only at 8 wk of age ( Figure 7A, top) . This was confirmed by another primer set amplifying MyBP-C(ϩ) cDNA as a 118-base pair product ( Figure 7A, bottom) . Although, the proportion of the expression of MyBP-C(Ϫ) versus MyBP-C(ϩ) is different among individual animals examined, MyBP-C(Ϫ) is dominantly expressed in ventricles in all postnatal developmental stages, whereas MyBP-C(ϩ) is dominantly expressed in the atria of older mice.
Expression of Cardiac MyBP-C Protein in the Aged Mouse Heart
To further examine the expression of MyBP-C(ϩ) protein in the aged mouse atria, we tried to raise a specific antibody for MyBP-C(ϩ) recognizing the unique 10 amino acid insertion but we were unsuccessful after several immunizations. Western blotting using an anti-MyBP-C antibody (␣ccp), which recognizes both of MyBP-C(Ϫ) and MyBP-C(ϩ) shows that the total amount of ventricular MyBP-C expression is increased at 12 wk of age and then decreased at Ͼ20 mo of age. In contrast, the expression of the total amount of atrial MyBP-C, MyBP-C(Ϫ) plus MyBP-C(ϩ), was constant at all three stages examined ( Figure 7B ). In aged mouse hearts (Ͼ 20 mo of age), ventricular MyBP-C exhibited striated sarcomeric pattern colocalizing with myosin ( Figure 8, A and B) ; however, atrial MyBP-C was diffusely localized in the cytoplasm despite the striated sarcomere formation stained with anti-myosin antibody (Figure 8, C and D) . These results indicate that the localization of MyBP-C is specifically stage and tissue (aria versus ventricles) regulated. According to the dominant expression of MyBP-C(ϩ) in aged mouse demonstrated by RT-PCR, diffusely localized MyBP-C proteins in aged atria are likely the MyBP-C(ϩ) form. Chicken cardiomyocytes were transfected with pGMC(Ϫ) or pEGFP-C3 (nonfused GFP vector). Three days after the transfection, cells were fixed and immunostained with A4.1045, specific for sarcomeric myosin heavy chain (B and D); Pc72C, specific for M-line connectin/titin (F); or C315, specific for chicken cardiac MyBP-C (H). Distribution of GFP-alone (A) and localization of GMC(Ϫ) (C, E, and G) were observed using its green fluorescence. The inserts show the enlarged image (3.5ϫ) of GFP or GMC(Ϫ) (green) and the corresponding sarcomere protein (red). Bar, 40 m. 
DISCUSSION
We found a novel splicing variant of MyBP-C/C-protein mRNA that has an additional 30 nucleotide sequence, resulting in a 10 amino acid insertion in the C9 domain, which is known as the connectin/titin binding region. We term this insertion-plus variant MyBP-C(ϩ) and the previously described insertion-minus MyBP-C MyBP-C(Ϫ). A 30-base pair insertion sequence (exon 31A) was found in the cardiac MyBP-C genomic sequence previously reported as an intron sequence between exon 30 and 31B. A consensus splice donor site, gt, was found at the 5Ј end of this intron, whereas two consensus acceptor sites were found with 30-base pair distance; one followed by exon 31A and the other followed by exon 31B. Cardiac MyBP-C is coded by a single gene. MyBP-C(ϩ) contains the identical coding sequence with a 30-base pair insertion; therefore, the mRNAs encoding these two isoforms of mouse cardiac MyBP-C are generated by an alternative splicing mechanism using the two acceptor sites regulated in a spatial and temporal manner. Similar internal splicings have been found in other genes to produce multiple isoforms at different developmental stages and in different tissues (Paul et al., 1986; reviewed in Breitbart et al., 1987; Magnuson et al., 1991) , including human and mouse fibronectin (Tamkun et al., 1984; Kornblihtt et al., 1985; reviewed in Schwarzbauer, 1991) . Biochemical analyses demonstrated several unique characteristics of MyBP-C(ϩ) compared with MyBP-C(Ϫ). In a cosedimentation assay, baculovirus-derived MyBP-C(ϩ) decreased binding affinity to connectin/titin and myosin filaments, whereas MyBP-C(Ϫ) showed a very similar binding affinity as native MyBP-C(Ϫ) described previously (Alyonycheva et al., 1997) . These results indicate the bacu- Novel Cardiac MyBP-C Splicing Variant lovirus derived MyBP-C(Ϫ) and the native MyBP-C(Ϫ) have very similar protein structures, but the 10 amino acid insertion at C9 domain changes its structure.
Six of 10 amino acid residues are hydrophobic, and these hydrophobic residues likely disrupt the ␣-helical stretch of MyBP-C(Ϫ) and replace it with beta-sheets at the C9 domain according to the Chou-Fasman protein secondary analyses of a GENETYX program. Because C8, C9, and C10 domains of MyBP-C are known to directly bind to a subset of Ig domains of connectin/titin (Freiburg and Gautel, 1996) , conformational changes due to the 10 amino acid insertion will decrease the association between MyBP-C and connectin/ titin. In addition, our experiments showed that the insertion into the C9 domain significantly decreased the binding to myosin filaments. The major myosin-binding domain of cardiac and skeletal MyBP-C was mapped at the carboxylterminal C10 domain (Okagaki et al., 1993; Alyonycheva et al., 1997) , but a recent report from Welikson and Fischman demonstrated that C7-C9 domains of the chicken skeletal MyBP-C also have an ability to bind with myosin (Welikson and Fischman, 2002) . Therefore, we assume that the inserted 10 amino acids in the C9 domain modify the structure of MyBP-C, resulting in alteration of conformation or direction of the C10 domain, which is important for binding with myosin, or the inserted 10 amino acids directly reduced binding to myosin filaments.
Supporting these in vitro binding assays, transfection experiments showed that GFP-MyBP-C(ϩ) was not effectively incorporated into sarcomere structures compared with GFPMyBP-C(Ϫ). Because MyBP-C(ϩ) could still bind to myosin filaments and connectin/titin with lower affinity, it sometimes associated with myofibrils, but it could not fully compete with and replace the endogenous chick MyBP-C protein, which does not include the 10 amino acid insertion (Yasuda et al., 1995) . We could not fully explain why MyBP-C(ϩ) is sometimes incorporated into myofibrils and sometimes diffusely distributed in the cytoplasm. It may be due to the different accumulation level of the MyBP-C(ϩ) in different cells or the timing of association of MyBP-C(ϩ) with sarcomeric components during sarcomere assembly.
The carboxyl-terminus end of MyBP-C is known to be important for sarcomere assembly, and expression of the carboxyl-terminus deletion mutants impaired the endogenous sarcomeric structure in the transfected myocytes (Gil- McConnell et al., 1999 McConnell et al., , 2001 Flavigny et al., 1999; Yang et al., 1998 Yang et al., , 1999 . We confirmed these results in Ͼ50% of the cells transfected with the several carboxylterminus deletion mutants. In our hands, GMC⌬10(Ϫ) showed the strongest effect on sarcomere disorganization in chicken cardiomyocytes followed by GMC⌬10(ϩ), GMC⌬9-10, and then GMC⌬7-10, indicating that the C10 deletion mutants have the strongest effects and that further truncation decreases the effects. Because MyBP-C binds to connectin/titin through C8 -C10 domains, the C10 deletion mutant is expected to bind connectin/titin with higher affinity than other deletion mutants.
We hypothesized that the lack of myosin binding but the preserved connectin/titin binding may cause the severe effects on sarcomere disorganization. These mutants could be replaced with the endogenous MyBP-C more effectively because of partially reserved binding to connectin/titin. Accordingly, GMC⌬7-10, which lacks both connectin/titin and myosin binding, showed the mildest effects on sarcomere disorganization, but still Ͼ50% of the transfected cells with GMC⌬7-10 showed disorganized sarcomere structure. We assume that interaction with other sarcomeric proteins through domain C0 -C6 of GMC⌬7-10 is responsible for the effects, including the N-terminal myosin S2 binding site (Gruen and Gautel, 1999) .
Surprisingly, MyBP-C(ϩ) disorganizes sarcomere structure as effectively as carboxyl-terminus deletion mutant GMC⌬7-10, showing a similar deleterious effect on sarcomeres. As assessed by mRNA levels at least, MyBP-C(ϩ) is dominantly expressed in aged mouse atria; therefore, it may act as a disruptive polypeptide via a dominant-negative effect on remaining MyBP-C(Ϫ) or it may partially compensate for the decreased expression of MyBP-C(Ϫ) in aged atria. It is generally accepted that the aged heart is associated with a number of characteristic morphological, histological, biochemical, and functional changes, including a reduction in the number of myocytes, the development of cardiac fibrosis, diastolic dysfunction, and a decrease in the intracellular response to ␤-adrenergic stimulation (reviewed in Roffe, 1998) . These changes are associated with hypertrophy as a result of a net decrease in the number of cardiomyocytes (Fleg, 1986) and isoform transition of myosin heavy chain (MHC) from ␣-MHC to ␤-MHC in rat ventricles (Lompre et al., 1984; Schuyler and Yarbrough, 1990; Wahr et al., 2000) . We have not examined the molecular mechanisms explaining the switch from MyBP-C(Ϫ) to MyBP-C(ϩ) and its effects on aged atrium nor have we investigated whether any novel cardiac MyBP-C isoform is expressed in other animals besides the mouse. But interestingly, it has been demonstrated that senescent rat atrial myocytes displayed abnormal myofilament arrays (Feldman and Navaratnam, 1981) .
In summary, we found a novel alternatively spliced form of cardiac MyBP-C that is abundantly expressed in aged mouse atria. This isoform, MyBP-C(ϩ), shows a decreased binding to myosin filaments and connectin/titin and a decreased incorporation into sarcomere structure, suggesting it is involved in the morphological and functional changes of cardiac muscle during aging.
